<DOC>
	<DOCNO>NCT00986973</DOCNO>
	<brief_summary>The aim pilot study determine change brain glucose metabolism gray matter patient Phenylketonuria ( PKU ) whether administration Sapropterin ( KUVAN ) therapy improve deficit .</brief_summary>
	<brief_title>Fluorodeoxyglucose Positron Emission Tomography ( FDG PET ) Findings Patients With Phenylketonuria Before After KUVAN Therapy</brief_title>
	<detailed_description>Phenylketonuria ( PKU ) autosomal recessive disorder result deficiency phenylalanine hydroxylase , convert phenylalanine tyrosine . Phenylalanine hydroxylase one three aromatic amino acid hydroxylases utilizes tetrahydrobiopterin ( BH4 ) cofactor . The published report indicate alter energy metabolism brain patient PKU . Phenylalanine metabolites appear impair several aspect brain energetics include : ( 1 ) Inhibition glucose uptake ; ( 2 ) diminish glycosylation cytoskeletal protein ; ( 3 ) Inhibition pyruvate kinase ; ( 4 ) reduce flux glycolysis . Studies vivo magnetic resonance spectroscopy demonstrate phenylalanine-responsive abnormality cerebral energy metabolism . Positron Emission Tomography ( PET ) scan fluorodeoxyglucose ( FDG-PET ) non-invasive method measure regional glucose metabolic rate high resolution absolute quantitation . To date technology use single case report investigation white matter abnormality small number patient PKU . The aim pilot study determine change brain glucose metabolism gray matter patient PKU whether Sapropterin ( KUVAN ) improve deficit . This study also elucidate relationship hyperphenylalaninemia , phenylalanine intake diet , alter brain glucose handle neurocognitive profile patient PKU KUVAN therapy .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>1 . Males females age 18 year 2 . Subject must able give independent inform consent 3 . Girls must negative urine pregnancy test must use acceptable method contraception , include abstinence , barrier method ( diaphragm condom ) , DepoProvera , oral contraceptive , duration study . 4 . Subject must confirm diagnosis PKU 5 . Subjects Phenylalanine ( Phe ) level 10 mg/dL 6 . Subjects na√Øve KUVAN therapy receive KUVAN 6 month screen 1 . Pregnancy 2 . Cognitive deficit result physical trauma ( e.g . subject history severe birth trauma ) . 3 . Neurologic comorbidities include history stroke seizure disorder . 4 . Laboratory abnormality indicate clinically significant hepatic disease Aspartate aminotransferase ( AST ) &gt; 2.0 time upper limit normal , Alanine transaminase ( ALT ) &gt; 2.0 time upper limit normal , Prothrombin Time ( PT ) &gt; 2.0 time upper limit normal , Partial Thromboplastin Time ( PTT ) &gt; 2.0 time upper limit normal 5 . Subjects use medication steroid , insulin glucagon may interfere result PET scan . 6 . Subjects use medication inhibit folate metabolism methotrexate 7 . Subjects use medication know affect nitric oxidemediated vasorelaxation . 8 . Subjects use Levodopa 9 . Treatment KUVAN past 6 month study entry . 10 . Treatment investigational product last 90 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PKU</keyword>
	<keyword>BH4</keyword>
	<keyword>KUVAN</keyword>
	<keyword>PET scan</keyword>
	<keyword>Neurodevelopment</keyword>
</DOC>